Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, international, double-blind randomized Phase III study to evaluate the
pathological complete response (pCR) according to Chevalier classification between
Fulvestrant® and the combination of Fulvestrant® plus Palbociclib as neoadjuvant therapy of
hormone-sensitive patients with operable luminal breast cancer.
Eligible patients will be assessed upfront using the OncotypeDX® molecular test (Recurrence
Score <31).
Phase:
Phase 3
Details
Lead Sponsor:
International Cancer Research Group, United Arab Emirates